<DOC>
	<DOC>NCT00394446</DOC>
	<brief_summary>Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.</brief_summary>
	<brief_title>Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1. Advanced or Metastatic Cancer 2. Measurable / Evaluable Disease 3. Karnofsky score greater than or equal to 70% 4. Adequate Hematology / Organ function 5. No Baseline peripheral or central neuropathy above grade 1 1. Hypersensitivity to Cremophor EL 2. Pregnant or Lactating 3. Spinal Cord Compression 4. Preexisting Dementia / Cognitive Disfunction 5. Require Neupogen or Neulasta to Maintain Neutrophil Count 6. Have Primary Brain Cancer 7. Have history of Ischemic Heart Disease 8. Have Diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Refractory</keyword>
	<keyword>Brain</keyword>
</DOC>